Omidria (Ketorolac, Phenylephrine)

Ketorolac inhibits cyclooxygenase enzymes, which reduces the synthesis of prostaglandins—key mediators of inflammation and pain. By lowering prostaglandin levels in ocular tissues, ketorolac helps control inflammation and discomfort associated with eye surgery.

The dosing regimen for Omidria is determined by the prescribing ophthalmologist based on the specific surgical procedure and patient needs. The product is supplied as a ready‑to‑use ophthalmic solution, and the prescriber sets the volume and timing of each intra‑ocular instillation.

Safety of Omidria in pregnancy and lactation has not been established. It should be used only if the potential benefit justifies any potential risk to the fetus or infant, and the decision should be made by the treating physician.

To order Omidria, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India supplies hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Unlike single‑agent mydriatics, Omidria combines a potent NSAID with phenylephrine, offering both anti‑inflammatory relief and sustained pupil dilation in one formulation. This dual action can simplify peri‑operative regimens compared with using separate NSAID drops and mydriatic agents.

Store Omidria at room temperature, preferably below 25 °C. Keep the vial in its original packaging, protect it from direct light and moisture, and avoid freezing. Do not refrigerate unless specifically instructed by the supplier.

Omidria is administered as an intra‑ocular (ophthalmic) solution. The prescribed volume is instilled directly into the eye, typically by the surgeon at the start of the procedure and, if required, during the postoperative period as directed.

Serious risks include severe allergic reactions such as anaphylaxis, significant increases in intra‑ocular pressure that could threaten optic nerve health, corneal complications, and systemic hypertension from phenylephrine. Immediate medical attention is required if any of these occur.

Patients with known hypersensitivity to ketorolac, phenylephrine, or any component of the formulation should not use Omidria. It is also contraindicated in individuals with narrow‑angle glaucoma, uncontrolled hypertension, or those taking MAO inhibitors without careful medical supervision.